Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials

被引:3
作者
Bortolot, Martina [1 ,2 ]
Cortiula, Francesco [2 ,3 ]
Fasola, Gianpiero [2 ]
De Ruysscher, Dirk [3 ]
Naidoo, Jarushka [4 ,5 ,6 ]
Hendriks, Lizza E. L. [7 ]
机构
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] Univ Hosp Udine, Dept Oncol, Piazzale Santa Maria Misericordia, I-33100 Udine, Italy
[3] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Radiat Oncol Maastro, Med Ctr, Maastricht, Netherlands
[4] Beaumont Hosp, Dublin, Ireland
[5] RCSI Univ Hlth Sci, Dublin, Ireland
[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands
关键词
NSCLC; Unresectable stage III; Special populations; Elderly; Frail; Comorbidities; PREDICTING RADIATION PNEUMONITIS; REAL-WORLD DATA; CONCURRENT CHEMORADIOTHERAPY; ELDERLY-PATIENTS; OLDER PATIENTS; RADIOTHERAPY; THERAPY; DURVALUMAB; NSCLC; CHEMORADIATION;
D O I
10.1016/j.ctrv.2024.102797
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Concurrent chemoradiotherapy (cCRT) followed by one year of consolidation durvalumab is the current standard-of-care for patients with unresectable stage III non-small cell lung cancer (NSCLC), of good functional status. However, cCRT and consolidation durvalumab may be challenging to administer for selected patient populations underrepresented or even excluded in clinical trials: older and/or frail patients; those with cardiovascular or respiratory comorbidities in which treatment-related adverse events may be higher, and patients with pre-existing autoimmune disorders for whom immunotherapy use is controversial. In this narrative review, we discuss the current evidence, challenges, ongoing clinical trials and potential future treatment scenarios in relevant subgroups of patients with locally advanced NSCLC, who are underrepresented in clinical trials.
引用
收藏
页数:9
相关论文
共 98 条
[1]   Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology [J].
Al-Kindi, Sadeer G. ;
Oliveira, Guilherme H. .
MAYO CLINIC PROCEEDINGS, 2016, 91 (01) :81-83
[2]   Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].
Altorki, Nasser K. ;
McGraw, Timothy E. ;
Borczuk, Alain C. ;
Saxena, Ashish ;
Port, Jeffrey L. ;
Stiles, Brendon M. ;
Lee, Benjamin E. ;
Sanfilippo, Nicholas J. ;
Scheff, Ronald J. ;
Pua, Bradley B. ;
Gruden, James F. ;
Christos, Paul J. ;
Spinelli, Cathy ;
Gakuria, Joyce ;
Uppal, Manik ;
Binder, Bhavneet ;
Elemento, Olivier ;
Ballman, Karla, V ;
Formenti, Silvia C. .
LANCET ONCOLOGY, 2021, 22 (06) :824-835
[3]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[4]   Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301) [J].
Atagi, Shinji ;
Mizusawa, Junki ;
Ishikura, Satoshi ;
Takahashi, Toshiaki ;
Okamoto, Hiroaki ;
Tanaka, Hiroshi ;
Goto, Koichi ;
Nakagawa, Kazuhiko ;
Harada, Masao ;
Takeda, Yuichiro ;
Nogami, Naoyuki ;
Fujita, Yuka ;
Kasai, Takashi ;
Kishi, Kazuma ;
Sawa, Toshiyuki ;
Takeda, Koji ;
Tomii, Keisuke ;
Satouchi, Miyako ;
Seto, Takashi ;
Ohe, Yuichiro .
CLINICAL LUNG CANCER, 2018, 19 (05) :E619-E627
[5]   Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer [J].
Atkins, Katelyn M. ;
Chaunzwa, Tafadzwa L. ;
Lamba, Nayan ;
Bitterman, Danielle S. ;
Rawal, Bhupendra ;
Bredfeldt, Jeremy ;
Williams, Christopher L. ;
Kozono, David E. ;
Baldini, Elizabeth H. ;
Nohria, Anju ;
Hoffmann, Udo ;
Aerts, Hugo J. W. L. ;
Mak, Raymond H. .
JAMA ONCOLOGY, 2021, 7 (02) :206-219
[6]   Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer [J].
Atkins, Katelyn M. ;
Rawal, Bhupendra ;
Chaunzwa, Tafadzwa L. ;
Lamba, Nayan ;
Bitterman, Danielle S. ;
Williams, Christopher L. ;
Kozono, David E. ;
Baldini, Elizabeth H. ;
Chen, Aileen B. ;
Nguyen, Paul L. ;
D'Amico, Anthony V. ;
Nohria, Anju ;
Hoffmann, Udo ;
Aerts, Hugo J. W. L. ;
Mak, Raymond H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (23) :2976-2987
[7]   Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].
Auperin, Anne ;
Le Pechoux, Cecile ;
Rolland, Estelle ;
Curran, Walter J. ;
Furuse, Kiyoyuki ;
Fournel, Pierre ;
Belderbos, Jose ;
Clamon, Gerald ;
Ulutin, Hakki Cuneyt ;
Paulus, Rebecca ;
Yamanaka, Takeharu ;
Bozonnat, Marie-Cecile ;
Uitterhoeve, Apollonia ;
Wang, Xiaofei ;
Stewart, Lesley ;
Arriagada, Rodrigo ;
Burdett, Sarah ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190
[8]   Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer [J].
Batra, Atul ;
Sheka, Dropen ;
Kong, Shiying ;
Cheung, Winson Y. .
BMC CANCER, 2020, 20 (01)
[9]   Radiation therapy in cancer patients with psoriasis. The fractionated daily dose and the Koebner phenomenon [J].
Ben-Yosef, R ;
Soyfer, V ;
Vexler, A .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (01) :21-23
[10]  
Berghmans Thierry, 2011, Ther Adv Med Oncol, V3, P127, DOI 10.1177/1758834011401951